Abstract
Multiple clinician-reported outcome measures exist for atopic dermatitis (AD) severity. However, there is no gold standard for use in clinical practice. To determine the measurement properties of the product of validated Investigator's Global Assessment for AD (vIGA) and body surface area (BSA) overall or divided into six categories (cBSA: 0%/0.1, <10%/10, <30%/30, <50%/50, <70%/70 and <90%/90-100%) and compare with other clinician-reported and patient-reported outcomes in adults and children with AD. We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n=653). vIGA*BSA and vIGA*cBSA had good convergent validity with BSA (Spearman's ρ=0.97 and 0.93), eczema area and severity index (ρ=0.94 and 0.92), and objective SCORAD (ρ=0.88 and 0.89); and weak-to-good convergent validity with Numeric Rating Scale average itch (ρ=0.22 and 0.22) and worst itch (ρ=0.27 and 0.28), Patient-Oriented Eczema Measure (ρ=0.44 and 0.43), Dermatology Life Quality Index (ρ=0.48 and 0.49), ItchyQOL (ρ=0.45 and 0.46), PROMIS Sleep Disturbance (ρ=0.46 and 0.37) and sleep-related impairment (ρ=0.31 and 0.31) in adults and/or children; very good discriminant validity for physician-reported global AD severity; good responsiveness to change of severity of AD and itch; and good reliability (intraclass correlation coefficient [95% confidence interval]: 0.72 [0.60-0.81] and 0.74 [0.62-0.82]) with no floor or ceiling effects. Thresholds for interpretability bands and clinically important difference were established. vIGA*BSA and vIGA*cBSA scores showed good convergent and discriminant validity, reliability, responsiveness and interpretability in adults and children with AD, and were feasible for use in clinical practice. vIGA*BSA and vIGA*cBSA had slightly lower convergent validity than EASI or objective SCORAD, but might be more efficient to collect and score.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of the European Academy of Dermatology and Venereology : JEADV
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.